P3, N=912, Completed, AbbVie | Active, not recruiting --> Completed

The CCDC6::JAK2 chimeric protein retains the CCDC6 coiled-coil domain and the JAK2 kinase domain. Dimerization of chimeric proteins through coiled-coil domains promotes JAK2 autophosphorylation leading to constitutive activation of the JAK/STAT signaling pathway.

This study aimed to compare the efficacy and safety of calcineurin inhibitor monotherapy (CNI) versus combination therapy [CNI and tofacitinib (TOF) or cyclophosphamide (CTX)] as initial immunosuppressive regimens for MDA5+DM. In our study, combination therapy may improve survival prognosis in MDA5+ DM patients. Nevertheless, vigilant monitoring for opportunistic infections during treatment is essential.

Although the JAK1/2 inhibitor Ruxolitinib is clinically approved, its efficacy is limited by toxicity to normal cells and the development of drug resistance...Moreover, through a compound screen, followed by chemical proteomics and compound optimization, WWQ-03-012 is discovered, which selectively degrades mutant JAK2, induces primary leukemia cells death, and inhibits MPN progression through targeting DESI2 enzymatic activity in vitro and in vivo. These studies provide a novel therapeutic strategy against mutated JAK2 signaling in MPN and sAML.

P4, N=60, Recruiting, All India Institute of Medical Sciences, Bhubaneswar | Not yet recruiting --> Recruiting

P2, N=176, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.

P=N/A, N=80, Recruiting, AbbVie | Trial completion date: Mar 2027 --> Dec 2026 | Trial primary completion date: Mar 2027 --> Dec 2026

P1/2, N=24, Not yet recruiting, University of Colorado, Denver

P4, N=36, Recruiting, Novartis Pharmaceuticals | N=54 --> 36

P=N/A, N=93, Not yet recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto

P=N/A, N=120, Recruiting, Pfizer | Trial completion date: Aug 2026 --> Mar 2026 | Trial primary completion date: Aug 2026 --> Mar 2026